NAVIDEA BIOPHARMACEUTICALS I (NAVB)

US63937X2027 - Common Stock

0.0779  0 (-2.99%)

Fundamental Rating

0

Overall NAVB gets a fundamental rating of 0 out of 10. We evaluated NAVB against 572 industry peers in the Biotechnology industry. NAVB has a bad profitability rating. Also its financial health evaluation is rather negative. NAVB is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NAVB has reported negative net income.
In the past year NAVB has reported a negative cash flow from operations.
NAVB had negative earnings in each of the past 5 years.
In the past 5 years NAVB reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of NAVB (-209.43%) is worse than 93.23% of its industry peers.
Industry RankSector Rank
ROA -209.43%
ROE N/A
ROIC N/A
ROA(3y)-239.03%
ROA(5y)-242.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NAVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

NAVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NAVB has more shares outstanding
NAVB has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -70.66, we must say that NAVB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -70.66, NAVB is doing worse than 98.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -70.66
ROIC/WACCN/A
WACC9.82%

2.3 Liquidity

NAVB has a Current Ratio of 0.84. This is a bad value and indicates that NAVB is not financially healthy enough and could expect problems in meeting its short term obligations.
NAVB has a worse Current ratio (0.84) than 92.90% of its industry peers.
A Quick Ratio of 0.79 indicates that NAVB may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.79, NAVB is doing worse than 93.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.79

More info and screens

0

3. Growth

3.1 Past

The earnings per share for NAVB have decreased strongly by -39.35% in the last year.
Looking at the last year, NAVB shows a very negative growth in Revenue. The Revenue has decreased by -87.65% in the last year.
The Revenue for NAVB have been decreasing by -48.49% on average. This is quite bad
EPS 1Y (TTM)-39.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.1%
Revenue 1Y (TTM)-87.65%
Revenue growth 3Y-53.62%
Revenue growth 5Y-48.49%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NAVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NAVB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NAVIDEA BIOPHARMACEUTICALS I

NYSEARCA:NAVB (10/5/2023, 8:04:00 PM)

0.0779

0 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2023-08-11/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.76%
Ins Owner Change0%
Market Cap7.80M
Analysts82.86
Price Target5.1 (6446.85%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 118.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -209.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.03%
ROA(5y)-242.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 241.56%
Cap/Sales 389.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.79
Altman-Z -70.66
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)474.48%
Cap/Depr(5y)298.68%
Cap/Sales(3y)233.93%
Cap/Sales(5y)142.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.65%
Revenue growth 3Y-53.62%
Revenue growth 5Y-48.49%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.6%
OCF growth 3YN/A
OCF growth 5YN/A